Middletown Life

Author: Roberts Communications

CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform

February 12, 2026
Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II

January 26, 2026
CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 8, 2026
Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease

December 15, 2025
CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy

December 9, 2025